Research Activity

GRANT AWARDS

Dr. Luka Pocivavsek

Title: A Geometric and Morphoelastic Study of Aortic Dissection Evolution
Funding Organization: National Institutes of Health/ National Heart, Lung, and Blood Institute
Amount: $2,547,808
Summary: To utilize modern approaches in differential geometry, continuum mechanics, and computer vision to discover and characterize high-risk geometric structures within computed tomography angiography (CTA) data of fragile aortas.

Dr. Tanya Zakrison

Title: PRECISE: Prevention through Referral, Compensation, and Integrating Structural Equity in Hospital-Based Violence Intervention
Funding Organization: Department of Justice
Amount: $997,357
Summary: American youth experience pervasive exposure to gun violence, which results in elevated risk of PTSD, future firearm-related injury, criminal justice system involvement, trauma recidivism, and death. To address the gaps of HVIP, promote the civil rights of at-risk youth, and protect the public from ongoing propagation of violence on the South Side of Chicago, we propose a community violence intervention (CVI) that involves expanding the UChicago Medicine HVIP to close the “youth gap” and integrate novel structural equity components.

INVESTIGATOR AUTHORED CLINICAL TRIALS

Principle Investigator:
Dr. Xavier Keutgen

Title: Preoperative PRRT versus surgical cytoreduction alone in metastatic pancreatic neuroendocrine tumors to the liver: A Phase II multi-institutional trial
Primary Objective: To determine whether preoperative PRRT prior to hepatic cytoreduction increases progression free survival (PFS1) (when compared to cytoreduction alone) in patients with metastatic PanNETs to the liver. UChicago lead site and 2 sub-sites
Subjects Anticipated: 52

Principle Investigator:
Dr. Sarah Faris

Title: The CUPID trial: Collaborative Urological Prosthetics Investigation Directive Research Group
Clinicaltrial.gov: NCT0510065
Primary Objective: Confirm that the 24-hour AUA ED Guideline compliant peri-operative antibiotic regimen is sufficient to prevent post-operative infections.
UChicago lead site and 11 sub-sites
Subjects Anticipated: 800

Principle Investigator:
Dr. Scott Eggener

Title: MRI Screening in Men at High Risk of Developing Prostate Cancer
Clinicaltrial.gov: NCT05512754
Primary Objective: Determine whether MRI screening can improve the detection
UChicago lead site and 1 sub-site.
Subjects Anticipated: 250

Title: Randomized controlled trial of anti-inflammatory medications in patients with elevated serum prostate-specific antigen
Primary Objective: The purpose of this study is to assess the impact of ibuprofen in men with elevated serum PSA.
Subjects Anticipated: 180

Principle Investigator:
Dr. Maria Lucia Madariaga

Title: Survey Study of Thoracic Patients Undergoing Frailty Screening
Primary Objective: To gauge patient opinions on frailty screening in clinic through Likert surveys
Subjects Anticipated: 150

Title: National Provider Survey on Perceptions of Frailty in Thoracic Surgery Patients
Primary Objective: By learning more about the current opinions and experiences of thoracic surgeons in the US with respect to treating frail patients, we will determine if efforts need to be made to educate thoracic surgeons on the importance of assessing and mitigating frailty in the pre-operative setting.
Subjects Anticipated: 3500

Principle Investigator:
Dr. Summer Hanson

Title: A pilot study treating radiation-injury with autologous fat transfer
Primary Objective: This is a single-arm, prospective pilot study that will objectively assess outcomes in patients electively undergoing autologous fat transfer (AFT) for breast or chest wall reconstruction.
Subjects Anticipated: 10

Principle Investigator:
Dr. Piotr Witkowski

Title: Novel desensitization protocol for highly sensitized patients to allow for successful kidney transplantation. A pilot study.
Clinicaltrial.gov: NCT05345717
Primary Objective: The purpose of the research is to determine whether belatacept, in conjunction with a proteasome inhibitor can be used to safely increase the likelihood of finding an acceptable donor for highly human leukocyte antigens (HLA) sensitized kidney transplant candidates.
Subjects Anticipated: 5